Revance's Botox Rival Receives USFDA Nod

By Indu Tyagi Ketan , 19 October, 2022

DaxibotulinumtoxinA (Daxxify), Revance's long-awaited Botox rival, has officially received FDA approval, as the company is now gearing up to establish its brand. Daxxify is an intravenous neuromodulator similar to Botox; its novel peptide exchange technology temporarily eases the moderate to severe glabellar (frown) lines. 

The trials revealed that a single injection had a significant anti-wrinkle impact on durational effects were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The chief differentiator for Daxxify is its endurance; it can last six months and has even proven effective for up to nine months in some individuals, vis-a-vis Botox injections that last only for three months.

Daxxify was initially scheduled to receive FDA approval in November 2020, but the epidemic slowed inspection. After visiting Revance's production facility, inspectors discovered quality control and record-keeping issues. The FDA then issued Revance a detailed response letter in October of last year. Soon after,  the FDA approved the changes in July after Revance resolved all five problems mentioned in the Complete Response Letter. 

In a separate report, Goldman Sachs predicted that Revance's Daxxify will cost about 30% more than its competitors, even though pricing has not yet been made public. This cost considers the extended value proposition for both doctors and patients. Revance's stock rose 18% in September post the FDA's approval, which is expected to end Botox's long-standing dominance in the aesthetics industry.

USFDA-Approves-DAXXIFY

Latest News

USFDA-Approves-DAXXIFY
Biodiesels to Recycle Gold in Place of Fossil Fuels

Recycling precious metals is growing nowadays with the transition to clean energy. The transformation requires the usage of renewables to increase efficiency. Gold is an essential metal widely used in electronics, aerospace, and other industries…

Read More

USFDA-Approves-DAXXIFY
Gasoline Prices to Rise in Summer 2024

The oil and gas industry has witnessed various changes since the beginning of 2024. The countries worldwide are experiencing oil shortages due to geopolitical crises between major oil-producing nations. However, gasoline prices are expected to…

Read More

USFDA-Approves-DAXXIFY
Declining Growth Rate Of ESG Funds In The United States

Globally, nations are investing mindfully in sustainable development to achieve clean energy transition goals in the next three decades. Developed countries like the United States are engaged in sustainable investments. However, the ESG (environment…

Read More

USFDA-Approves-DAXXIFY
Advanced Economies May Suffer Downfall With Less Energy Storage for Future

Globally, the countries are adopting renewables to go greener by 2050. Countries are focusing on utilizing renewables as their energy source. It is to support the clean energy transition by limiting carbon and other harmful gas emissions. However…

Read More

USFDA-Approves-DAXXIFY
Advanced Economies May Suffer Downfall With Less Energy Storage for Future

Globally, the countries are adopting renewables to go greener by 2050. Countries are focusing on utilizing renewables as their energy source. It is to support the clean energy transition by limiting carbon and other harmful gas emissions. However…

Read More

Author Pic
Indu Tyagi Ketan

Chief Strategy Officer